Axa’s Editas Medicine EDIT Stock Holding History

Axa’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-95,000	Closed	-$741K	–	1085
2023 Q3	$741K	Sell	95,000 -10,500	-10%	-$90K	﹤0.01%	881
2023 Q2	$868K	Sell	105,500 -5,800	-5%	-$50.5K	﹤0.01%	859
2023 Q1	$807K	Hold	111,300	–	–	﹤0.01%	903
2022 Q4	$987K	Buy	+111,300	New	+$1.22M	﹤0.01%	886
2021 Q4	–	Sell	-10,500	Closed	-$431K	–	1204
2021 Q3	$431K	Buy	+10,500	New	+$575K	﹤0.01%	1084

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Axa's EDIT Position: Q4 2023 in Review

Axa sold out of Editas Medicine (EDIT) in Q4 2023, closing a stake of 95,000 shares — an estimated $741K sold.

Axa first reported a position in EDIT in Q3 2021 and held it in 5 quarters. The position peaked at $987K in Q4 2022. 225 funds tracked by Wall St. Rank hold EDIT as of Q4 2023.

Axa reported no remaining Editas Medicine position as of Q4 2023 after selling out during the quarter.
Axa sold 95,000 Editas Medicine shares in Q4 2023, an estimated $741K.
Axa first reported a position in Editas Medicine in Q3 2021 and held it in 5 quarters.
Axa's Editas Medicine position peaked at $987K in Q4 2022.
225 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2023.

Based on Axa's 13F filing for Q4 2023, filed 14 Feb 2024.